Baird Financial Group’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Baird Financial Group’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-86,563	Closed	-$1.54M	–	1395
2018 Q3	$1.54M	Sell	86,563 -3,777	-4%	-$64.8K	0.01%	738
2018 Q2	$1.25M	Buy	90,340 +321	+0.4%	+$3.81K	0.01%	776
2018 Q1	$818K	Buy	+90,019	New	+$497K	0.01%	885

Other funds holding ECYT

OTC

Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return

Claro Advisors Boston, Massachusetts $953M AUM 24.79% 1-Year Est. Return

Baird Financial Group's ECYT Position: Q4 2018 in Review

Baird Financial Group sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 86,563 shares — an estimated $1.54M sold.

Baird Financial Group first reported a position in ECYT in Q1 2018 and held it in 3 quarters. The position peaked at $1.54M in Q3 2018. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.

Baird Financial Group reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
Baird Financial Group sold 86,563 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $1.54M.
Baird Financial Group first reported a position in Endocyte, Inc. Common Stock in Q1 2018 and held it in 3 quarters.
Baird Financial Group's Endocyte, Inc. Common Stock position peaked at $1.54M in Q3 2018.
2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.

Based on Baird Financial Group's 13F filing for Q4 2018, filed 14 Feb 2019.